0
USD ▼
EUR USD GBP
+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Gene Fusion Testing Market by Technology, Sample Type, Application, End User - Global Forecast to 2030- Product Image
Gene Fusion Testing Market by Technology, Sample Type, Application, End User - Global Forecast to 2030- Product Image
Sale

Gene Fusion Testing Market by Technology, Sample Type, Application, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 184 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 5924686
UP TO EUR$697USDGBP OFF until Dec 31st 2025
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Gene Fusion Testing Market grew from USD 480.95 million in 2024 to USD 541.32 million in 2025. It is expected to continue growing at a CAGR of 12.45%, reaching USD 972.55 million by 2030.

Setting the Stage for a New Era in Molecular Diagnostics

Gene fusion testing has emerged as an indispensable tool in modern molecular diagnostics, revolutionizing the way clinicians and researchers detect and characterize oncogenic drivers and other genetic rearrangements. By enabling precise identification of fusion genes, this suite of technologies underpins targeted therapy selection, prognostic assessment, and patient stratification across a broad spectrum of hematologic malignancies, solid tumors, and rare disorders. The convergence of advanced sequencing methods and robust bioinformatics pipelines has accelerated the adoption of fusion testing, empowering laboratories to deliver rapid and accurate results that directly impact patient outcomes.

This executive summary distills key trends, market dynamics, and strategic insights shaping the gene fusion testing landscape. Drawing on an in‐depth analysis of technological evolution, regulatory developments, and competitive positioning, it offers decision-makers an authoritative overview of transformative shifts and emergent opportunities. Each section builds on rigorous research to clarify segmentation nuances, regional growth drivers, and the cumulative effect of recent trade policy changes. The goal is to equip industry leaders, clinical laboratories, and research institutions with actionable intelligence to navigate a rapidly evolving marketplace and chart a course toward sustained innovation and growth.

Technological Convergence and Collaborative Innovation Reshaping the Field

The gene fusion testing landscape is undergoing a period of profound transformation driven by several converging forces. Breakthroughs in sequencing accuracy, throughput, and cost-efficiency have redefined the benchmarks for clinical and research applications. Platforms once relegated to large reference laboratories are now finding their way into decentralized settings, fostering a trend toward near-patient testing and expanding access in previously underserved regions. Complementing technological innovations, the integration of artificial intelligence-enabled analytics is enhancing the sensitivity and specificity of fusion detection, enabling the rapid interpretation of complex genomic rearrangements.

Concurrently, evolving regulatory frameworks across key markets are streamlining the approval pathways for diagnostic assays, encouraging the adoption of standardized laboratory-developed tests and paving the way for greater interoperability. Strategic partnerships between diagnostic vendors, academic consortia, and biopharmaceutical companies are accelerating co-development efforts, driving the creation of companion diagnostics tailored to novel targeted therapies. This collaborative momentum is set to reshape the competitive dynamic, with data-driven service offerings and turnkey testing solutions emerging as differentiators in a crowded field.

Adapting Supply Chains and Pricing Strategies in a Tariff-Influenced Market

The implementation of new United States tariffs in 2025 has introduced fresh complexities into the global gene fusion testing supply chain. Duties on imported reagents, consumables, and specialized instrumentation have exerted upward pressure on operating costs for diagnostic laboratories and research facilities. Organizations reliant on cross-border procurement have responded by diversifying supplier portfolios and stockpiling critical materials to mitigate exposure to fluctuating duty rates.

Despite these challenges, tier-one vendors have leveraged economies of scale and regional manufacturing hubs to cushion the impact of tariffs. By shifting production closer to end markets, they have preserved competitive pricing while safeguarding the continuity of reagent supply. In parallel, service providers have explored value-based contracting models with reagent manufacturers, aligning fees with performance metrics to offset incremental cost burdens. As trade policy continues to evolve, stakeholders that proactively optimize supply chain resilience and negotiate strategic partnerships will be best positioned to sustain margin performance and maintain timely delivery of diagnostic services.

Unpacking Market Segments to Reveal Growth Drivers

Detailed segmentation of the gene fusion testing market reveals nuanced adoption patterns and growth vectors across technology, specimen type, clinical application, and end-user category. Fluorescence in situ hybridization and immunohistochemistry remain entrenched in many diagnostic pathways due to their established workflows and regulatory familiarity, while reverse transcription polymerase chain reaction retains a niche for high-sensitivity, targeted analysis. The rapid ascent of next generation sequencing underscores a paradigm shift: targeted sequencing panels tailored to known fusion hotspots coexist alongside transcriptome-wide and whole genome sequencing approaches, enabling comprehensive fusion discovery and novel variant identification.

Specimen diversity further influences market dynamics, with peripheral blood sampling-pulled from plasma or serum fractions-delivering minimally invasive opportunities for monitoring disease burden longitudinally. Tissue-based analyses continue to rely on both formalin fixed paraffin embedded specimens and fresh frozen samples, ensuring robust detection in solid tumors. Application areas are equally varied, spanning hematologic indications such as leukemia and lymphoma to solid tumor oncology subsegments including breast, colorectal, lung, and prostate malignancies, as well as rare developmental and neuromuscular disorders where fusion drivers play a diagnostic role. End users span the spectrum from hospital-based and independent diagnostic laboratories to inpatient and outpatient clinical sites, supplemented by pharmaceutical R&D teams in both biotechnology startups and established pharma giants, along with academic centers and private research institutions advancing basic and translational science.

Diverse Regional Trajectories Shaping Global Adoption Patterns

Regional dynamics in gene fusion testing reflect heterogeneous levels of market maturity and investment priorities. The Americas boast an advanced infrastructure for genomic medicine, propelled by robust reimbursement frameworks in the United States and significant public and private research funding across Canada. Latin American nations are showing early signs of expansion in centralized testing hubs as healthcare systems modernize.

Europe, the Middle East, and Africa present a complex tapestry of adoption patterns. Western European countries benefit from harmonized regulatory standards and cross-border reimbursements, while emerging markets in the Middle East are increasing diagnostic spending through public health initiatives. Across Africa, pockets of academic excellence foster research collaborations, although broad-based clinical implementation is still in its infancy.

In Asia-Pacific, accelerated government-led precision medicine programs in China, Japan, and South Korea are catalyzing demand for advanced fusion assays. India’s burgeoning biotech sector is driving cost-sensitive innovation, and smaller markets such as Southeast Asia and Australia are expressing growing interest in decentralized testing capacities. This regional mosaic underscores the importance of tailored market entry strategies and partnerships aligned with local ecosystems.

Strategic Alliances and Competitive Forces Defining Market Leaders

The competitive landscape of gene fusion testing is defined by established sequencing powerhouses and agile specialty providers. Illumina maintains a commanding position with its comprehensive NGS platforms and expanding catalog of targeted fusion panels, while Thermo Fisher Scientific leverages synergy between its semiconductor sequencing technologies and integrated bioinformatics tools to offer end-to-end solutions. Agilent Technologies and QIAGEN complement these players with focused enrichment chemistries and assay designs that address niche applications.

Emerging companies are making strategic inroads through novel chemistry development and streamlined workflows tailored to rapid diagnostics. These challengers often partner with academic institutions to validate assay performance and secure co-development agreements with pharmaceutical firms. Concurrently, consolidation through mergers and acquisitions is reshuffling market share, as larger organizations seek to broaden their portfolios and integrate fusion testing capabilities within holistic molecular pathology offerings. The result is a dynamic environment where scale, innovation, and strategic alliances determine long-term leaders.

Proactive Strategies to Capitalize on Emerging Opportunities

Industry stakeholders seeking to capture growth in gene fusion testing should prioritize investments in scalable next generation sequencing infrastructure and cloud-based bioinformatics to support expansion into new applications and geographies. Collaborations with reagent suppliers and contract research organizations can enhance supply chain resilience and accelerate time to market for novel assays. Engaging payers early through real‐world evidence programs will facilitate reimbursement pathways and reduce adoption barriers in cost-sensitive markets.

Developing modular testing platforms that accommodate both targeted panels and broader sequencing workflows can address diverse laboratory needs, while flexible pricing models tied to performance outcomes will resonate with budget-constrained customers. In parallel, forging partnerships with leading academic centers and patient advocacy groups will drive visibility and establish clinical utility across rare disease and oncology segments. Finally, proactive regulatory engagement and participation in standards-setting consortia will position organizations to shape the evolving landscape and secure a competitive edge.

Rigorous Data Collection and Validation Methods Ensuring Reliability

This analysis integrates primary and secondary research conducted through a multi-phase methodology. Initially, an exhaustive review of peer‐reviewed literature, regulatory filings, corporate disclosures, and industry databases was performed to establish foundational market parameters. Subsequently, a series of in-depth interviews with key opinion leaders, laboratory directors, procurement specialists, and technology vendors yielded qualitative insights into adoption drivers, cost structures, and workflow preferences.

Quantitative data collection involved surveying end users and aggregating shipment volumes, reagent consumption rates, and pricing benchmarks. Advanced statistical techniques, including regression analysis and scenario modeling, were applied to identify correlation trends and assess the impact of external factors such as tariffs. All findings underwent rigorous validation through cross-comparison with third-party databases and expert advisory panels to ensure accuracy and reliability. The comprehensive methodology provides a balanced and objective perspective on current market realities and future trajectories.

Synthesizing Key Insights to Guide Strategic Decision-Making

The gene fusion testing market stands at the intersection of technological innovation, shifting regulatory landscapes, and evolving clinical demands. The transition from conventional assays to next generation sequencing has unlocked new possibilities for comprehensive fusion detection, while tariff-induced supply chain challenges highlight the need for strategic resilience. Segmentation analysis underscores distinct growth opportunities across technology modalities, specimen types, and clinical applications, reinforced by dynamic regional adoption patterns and a competitive arena driven by both established and emerging players.

Decision-makers equipped with these insights can navigate the complexities of the market, leveraging targeted investments and partnerships to accelerate assay development and broaden application horizons. By aligning operational agility with a thorough understanding of regulatory and reimbursement ecosystems, organizations will be poised to deliver enhanced diagnostic value and maintain a leadership position in this transformative field.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Technology
    • Fluorescence In Situ Hybridization
    • Immunohistochemistry
    • Next Generation Sequencing
      • Targeted Next Generation Sequencing
      • Transcriptome Sequencing
      • Whole Genome Sequencing
    • Reverse Transcription Polymerase Chain Reaction
  • Sample Type
    • Blood
      • Plasma
      • Serum
    • Tissue
      • Formalin Fixed Paraffin Embedded
      • Fresh Frozen Tissue
  • Application
    • Hematology
      • Leukemia
      • Lymphoma
    • Oncology
      • Breast Cancer
      • Colorectal Cancer
      • Lung Cancer
      • Prostate Cancer
    • Rare Diseases
      • Developmental Disorders
      • Neuromuscular Disorders
  • End User
    • Diagnostic Laboratories
      • Hospital Based Laboratories
      • Independent Laboratories
    • Hospitals
      • Inpatient Facilities
      • Outpatient Clinics
    • Pharmaceutical Companies
      • Biotechnology Companies
      • Pharma Giants
    • Research Institutions
      • Academic Centers
      • Private Research Laboratories
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • NanoString Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Foundation Medicine, Inc.
  • Archer DX, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Gene Fusion Testing Market, by Technology
8.1. Introduction
8.2. Fluorescence in Situ Hybridization
8.3. Immunohistochemistry
8.4. Next Generation Sequencing
8.4.1. Targeted Next Generation Sequencing
8.4.2. Transcriptome Sequencing
8.4.3. Whole Genome Sequencing
8.5. Reverse Transcription Polymerase Chain Reaction
9. Gene Fusion Testing Market, by Sample Type
9.1. Introduction
9.2. Blood
9.2.1. Plasma
9.2.2. Serum
9.3. Tissue
9.3.1. Formalin Fixed Paraffin Embedded
9.3.2. Fresh Frozen Tissue
10. Gene Fusion Testing Market, by Application
10.1. Introduction
10.2. Hematology
10.2.1. Leukemia
10.2.2. Lymphoma
10.3. Oncology
10.3.1. Breast Cancer
10.3.2. Colorectal Cancer
10.3.3. Lung Cancer
10.3.4. Prostate Cancer
10.4. Rare Diseases
10.4.1. Developmental Disorders
10.4.2. Neuromuscular Disorders
11. Gene Fusion Testing Market, by End User
11.1. Introduction
11.2. Diagnostic Laboratories
11.2.1. Hospital Based Laboratories
11.2.2. Independent Laboratories
11.3. Hospitals
11.3.1. Inpatient Facilities
11.3.2. Outpatient Clinics
11.4. Pharmaceutical Companies
11.4.1. Biotechnology Companies
11.4.2. Pharma Giants
11.5. Research Institutions
11.5.1. Academic Centers
11.5.2. Private Research Laboratories
12. Americas Gene Fusion Testing Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Gene Fusion Testing Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Gene Fusion Testing Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Thermo Fisher Scientific Inc.
15.3.2. Illumina, Inc.
15.3.3. F. Hoffmann-La Roche Ltd
15.3.4. Agilent Technologies, Inc.
15.3.5. QIAGEN N.V.
15.3.6. Bio-Rad Laboratories, Inc.
15.3.7. NanoString Technologies, Inc.
15.3.8. BGI Genomics Co., Ltd.
15.3.9. Foundation Medicine, Inc.
15.3.10. Archer DX, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. GENE FUSION TESTING MARKET MULTI-CURRENCY
FIGURE 2. GENE FUSION TESTING MARKET MULTI-LANGUAGE
FIGURE 3. GENE FUSION TESTING MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GENE FUSION TESTING MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. GENE FUSION TESTING MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. GENE FUSION TESTING MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL GENE FUSION TESTING MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL GENE FUSION TESTING MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TARGETED NEXT GENERATION SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TRANSCRIPTOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL GENE FUSION TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL GENE FUSION TESTING MARKET SIZE, BY REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL GENE FUSION TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FORMALIN FIXED PARAFFIN EMBEDDED, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL GENE FUSION TESTING MARKET SIZE, BY FRESH FROZEN TISSUE, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL GENE FUSION TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL GENE FUSION TESTING MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DEVELOPMENTAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL GENE FUSION TESTING MARKET SIZE, BY NEUROMUSCULAR DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITAL BASED LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INDEPENDENT LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL GENE FUSION TESTING MARKET SIZE, BY INPATIENT FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL GENE FUSION TESTING MARKET SIZE, BY OUTPATIENT CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL GENE FUSION TESTING MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMA GIANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL GENE FUSION TESTING MARKET SIZE, BY ACADEMIC CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL GENE FUSION TESTING MARKET SIZE, BY PRIVATE RESEARCH LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 71. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 72. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 73. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 74. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 82. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 83. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 84. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 85. UNITED STATES GENE FUSION TESTING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 86. CANADA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 87. CANADA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 88. CANADA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 89. CANADA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 90. CANADA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 91. CANADA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 92. CANADA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 93. CANADA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 94. CANADA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 95. CANADA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 96. CANADA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 97. CANADA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 98. CANADA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 99. CANADA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 100. MEXICO GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 101. MEXICO GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 102. MEXICO GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 103. MEXICO GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 104. MEXICO GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 105. MEXICO GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. MEXICO GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 107. MEXICO GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 108. MEXICO GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 109. MEXICO GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 110. MEXICO GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 111. MEXICO GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 113. MEXICO GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 114. BRAZIL GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 115. BRAZIL GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 116. BRAZIL GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 117. BRAZIL GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 118. BRAZIL GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 119. BRAZIL GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 120. BRAZIL GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 121. BRAZIL GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 122. BRAZIL GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 123. BRAZIL GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 124. BRAZIL GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 125. BRAZIL GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 126. BRAZIL GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 127. BRAZIL GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 128. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 129. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 130. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 131. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 132. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 133. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 134. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 135. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 136. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 137. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 138. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 139. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 140. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 141. ARGENTINA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 142. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA GENE FUSION TESTING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 157. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 158. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 160. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 162. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 164. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 166. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 168. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 170. UNITED KINGDOM GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 171. GERMANY GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 172. GERMANY GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 173. GERMANY GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 174. GERMANY GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 175. GERMANY GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 176. GERMANY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 177. GERMANY GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 178. GERMANY GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 179. GERMANY GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 180. GERMANY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. GERMANY GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 182. GERMANY GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 183. GERMANY GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 184. GERMANY GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 185. FRANCE GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 186. FRANCE GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 187. FRANCE GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 188. FRANCE GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 189. FRANCE GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 190. FRANCE GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 191. FRANCE GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 192. FRANCE GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 193. FRANCE GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 194. FRANCE GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. FRANCE GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 196. FRANCE GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 197. FRANCE GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 198. FRANCE GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 199. RUSSIA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 200. RUSSIA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 201. RUSSIA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 202. RUSSIA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 203. RUSSIA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 204. RUSSIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 205. RUSSIA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 206. RUSSIA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 207. RUSSIA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 208. RUSSIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. RUSSIA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 210. RUSSIA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 211. RUSSIA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 212. RUSSIA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 213. ITALY GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 214. ITALY GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 215. ITALY GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 216. ITALY GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 217. ITALY GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 218. ITALY GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 219. ITALY GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 220. ITALY GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 221. ITALY GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 222. ITALY GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. ITALY GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 224. ITALY GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 225. ITALY GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 226. ITALY GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 227. SPAIN GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 228. SPAIN GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 229. SPAIN GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 230. SPAIN GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 231. SPAIN GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 232. SPAIN GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 233. SPAIN GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 234. SPAIN GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 235. SPAIN GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 236. SPAIN GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. SPAIN GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 238. SPAIN GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 239. SPAIN GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 240. SPAIN GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 256. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 258. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 260. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 262. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 264. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 266. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 268. SAUDI ARABIA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 270. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 272. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 274. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 276. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 278. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 280. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 282. SOUTH AFRICA GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 283. DENMARK GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 284. DENMARK GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 285. DENMARK GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 286. DENMARK GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 287. DENMARK GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 288. DENMARK GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 289. DENMARK GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 290. DENMARK GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 291. DENMARK GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 292. DENMARK GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 293. DENMARK GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 294. DENMARK GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 295. DENMARK GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 296. DENMARK GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 297. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 298. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 299. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 300. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 301. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 302. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 303. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 304. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 305. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 306. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 307. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 308. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 309. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 310. NETHERLANDS GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 311. QATAR GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 312. QATAR GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 313. QATAR GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 314. QATAR GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 315. QATAR GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 316. QATAR GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 317. QATAR GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 318. QATAR GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 319. QATAR GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 320. QATAR GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 321. QATAR GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 322. QATAR GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 323. QATAR GENE FUSION TESTING MARKET SIZE, BY PHARMACEUTICAL COMPANIES, 2018-2030 (USD MILLION)
TABLE 324. QATAR GENE FUSION TESTING MARKET SIZE, BY RESEARCH INSTITUTIONS, 2018-2030 (USD MILLION)
TABLE 325. FINLAND GENE FUSION TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
TABLE 326. FINLAND GENE FUSION TESTING MARKET SIZE, BY NEXT GENERATION SEQUENCING, 2018-2030 (USD MILLION)
TABLE 327. FINLAND GENE FUSION TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2030 (USD MILLION)
TABLE 328. FINLAND GENE FUSION TESTING MARKET SIZE, BY BLOOD, 2018-2030 (USD MILLION)
TABLE 329. FINLAND GENE FUSION TESTING MARKET SIZE, BY TISSUE, 2018-2030 (USD MILLION)
TABLE 330. FINLAND GENE FUSION TESTING MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
TABLE 331. FINLAND GENE FUSION TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2030 (USD MILLION)
TABLE 332. FINLAND GENE FUSION TESTING MARKET SIZE, BY ONCOLOGY, 2018-2030 (USD MILLION)
TABLE 333. FINLAND GENE FUSION TESTING MARKET SIZE, BY RARE DISEASES, 2018-2030 (USD MILLION)
TABLE 334. FINLAND GENE FUSION TESTING MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 335. FINLAND GENE FUSION TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, 2018-2030 (USD MILLION)
TABLE 336. FINLAND GENE FUSION TESTING MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
TABLE 337. FINLAND GENE FUSION TESTING MAR

Samples

Sample File DOWNLOAD NOW

Companies Mentioned

The companies profiled in this Gene Fusion Testing market report include:
  • Thermo Fisher Scientific Inc.
  • Illumina, Inc.
  • F. Hoffmann-La Roche Ltd
  • Agilent Technologies, Inc.
  • QIAGEN N.V.
  • Bio-Rad Laboratories, Inc.
  • NanoString Technologies, Inc.
  • BGI Genomics Co., Ltd.
  • Foundation Medicine, Inc.
  • Archer DX, Inc.

Table Information

Report AttributeDetails
No. of Pages184
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 541.32 Million
Forecasted Market Value ( USD ) by 2030 $ 972.55 Million
Compound Annual Growth Rate12.4%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Gene Fusion Testing Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F - Product Image

Gene Fusion Testing Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2020-2030F

  • Report
  • 182 Pages
  • Global
From
EUR$3,825USDGBP
EUR$4,500USDGBP
Gene Fusion Testing Market - A Global and Regional Analysis: Focus on Category, Technology, Indication, End User, and Region - Analysis and Forecast, 2025-2035 - Product Image

Gene Fusion Testing Market - A Global and Regional Analysis: Focus on Category, Technology, Indication, End User, and Region - Analysis and Forecast, 2025-2035

  • Report
  • 130 Pages
  • Global
From
EUR$4,900USDGBP
Gene Panel Market Size, Share & Trends Analysis Report By Product & Services (Test Kits, Testing Services), By Technique (Amplicon Based), By Design, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030 - Product Image

Gene Panel Market Size, Share & Trends Analysis Report By Product & Services (Test Kits, Testing Services), By Technique (Amplicon Based), By Design, By Application, By End-use, By Region, And Segment Forecasts, 2024 - 2030

  • Report
  • 100 Pages
  • Global
From
EUR$5,950USDGBP
Genomic Cancer Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F - Product Image

Genomic Cancer Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2019-2029F

  • Report
  • 185 Pages
  • Global
From
EUR$3,825USDGBP
EUR$4,500USDGBP
Deafness Susceptibility Gene Detection Kit Market by Technology, Application, End User, Mutation Type, Distribution Channel - Global Forecast to 2030 - Product Image

Deafness Susceptibility Gene Detection Kit Market by Technology, Application, End User, Mutation Type, Distribution Channel - Global Forecast to 2030

  • Report
  • 186 Pages
  • Global
From
EUR$3,545USDGBP
EUR$3,939USDGBP
Copyright © 2002-2025 Research and Markets. All Rights Reserved.
This website uses cookies to ensure you get the best experience. Learn more